Why is ascites always treated with a combination of furosemide and spironolactone? Why is the AST usually higher than ALT in alcoholic hepatitis? The Why? Series aims to answer your burning questions about the "dogma" of liver disease, using a combination of basic physiology, scientific evidence, and clinical experiential knowledge.
Preventative care in patients with liver disease is essential and complicated; when the liver goes down, it takes other organs down with it. In addition…
In this series, we will talk about the natural history of variceal bleeding, current standard of care, patients defined as high risk for treatment failure,…
You may have noticed that we often start antibiotics for patients with cirrhosis to prevent spontaneous bacterial peritonitis (SBP). Have you ever wondered why?
Lactulose and Rifaximin (Xifaxan) are standards of care for the prevention of overt hepatic encephalopathy in patients with cirrhosis. Have you ever wondered why? Join…
In a follow-up to an outstanding overview of NSBB therapy in liver disease, Part 2 of this series by Anahita Rabiee presents evidence in support of earlier use of NSBBs in cirrhosis. Read on!
In the first post from new LFN author Anahita Rabiee, we are gifted an authoritative review on the Whys and Hows of beta-blockade in decompensated cirrhosis! You definitely want to read this one!
In a very special installment of the Why Series, our adult and pediatric teams join forces to answer the question of how living donor liver transplantation came about in the United States. Read on!
In part 2 of our coagulopathy series, we take a deeper dive and learn the ways in which end-stage liver disease alters the body’s normal hemostatic mechanisms.
Patients with end-stage liver disease have elevated INRs. They bleed frequently and they clot perhaps more frequently. Do they need FFP before a paracentesis? What’s a TEG? These questions answered, and more, in our multi-part series on the coagulopathy of liver disease!
In Part 1 of this series, we reviewed what came BEFORE the MELD score—Child-Turcotte-Pugh classification. We additionally discussed the history behind MELD, what is included in its calculation and why, and how it is used in transplant listing. Is everyone excited for Part 2?
Do you have suggestions for topics within this series? Are you a fellow interested in contributing? Please feel free to reach out via Twitter to the fellow lead or to Liver Fellow Network directly. You can also e-mail us at firstname.lastname@example.org.